ATYR aTYR PHARMA INC

Nasdaq atyrpharma.com


$ 0.78 $ 0.00 (-0.34 %)    

Tuesday, 11-Nov-2025 18:47:23 EST
QQQ $ 625.21 $ 0.00 (0 %)
DIA $ 479.99 $ 0.00 (0 %)
SPY $ 685.17 $ 0.00 (0 %)
TLT $ 89.78 $ 0.00 (0 %)
GLD $ 379.81 $ 0.00 (0 %)
$ 0.7873
$ 0.78
$ 0.76 x 200
$ 0.81 x 250
-- - --
$ 0.68 - $ 7.29
2,799,779
na
77.14M
$ 1.09
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-07-2025 03-31-2025 10-Q
4 03-13-2025 12-31-2024 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-13-2024 06-30-2024 10-Q
7 05-02-2024 03-31-2024 10-Q
8 03-14-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-09-2023 06-30-2023 10-Q
11 05-09-2023 03-31-2023 10-Q
12 03-14-2023 12-31-2022 10-K
13 11-14-2022 09-30-2022 10-Q
14 08-15-2022 06-30-2022 10-Q
15 05-10-2022 03-31-2022 10-Q
16 03-15-2022 12-31-2021 10-K
17 11-12-2021 09-30-2021 10-Q
18 08-11-2021 06-30-2021 10-Q
19 05-14-2021 03-31-2021 10-Q
20 03-24-2021 12-31-2020 10-K
21 11-13-2020 09-30-2020 10-Q
22 08-13-2020 06-30-2020 10-Q
23 05-12-2020 03-31-2020 10-Q
24 03-26-2020 12-31-2019 10-K
25 11-14-2019 09-30-2019 10-Q
26 08-14-2019 06-30-2019 10-Q
27 05-14-2019 03-31-2019 10-Q
28 03-26-2019 12-31-2018 10-K
29 11-14-2018 09-30-2018 10-Q
30 08-14-2018 06-30-2018 10-Q
31 05-15-2018 03-31-2018 10-Q
32 03-20-2018 12-31-2017 10-K
33 11-14-2017 09-30-2017 10-Q
34 08-14-2017 06-30-2017 10-Q
35 05-11-2017 03-31-2017 10-Q
36 03-16-2017 12-31-2016 10-K
37 11-14-2016 09-30-2016 10-Q
38 08-10-2016 06-30-2016 10-Q
39 05-11-2016 03-31-2016 10-Q
40 03-30-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

RBC Capital analyst Brian Abrahams maintains aTyr Pharma (NASDAQ:ATYR) with a Sector Perform and lowers the price target fro...

Core News & Articles

aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in th...

 benzinga-bulls-and-bears-intel-fedex-cracker-barrel--and-markets-close-at-record-highs

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our t...

Core News & Articles

Wells Fargo analyst Derek Archila downgrades aTyr Pharma (NASDAQ:ATYR) from Overweight to Equal-Weight and lowers the price ...

Core News & Articles

RBC Capital analyst Brian Abrahams downgrades aTyr Pharma (NASDAQ:ATYR) from Outperform to Sector Perform and lowers the pri...

Core News & Articles

HC Wainwright & Co. analyst Joseph Pantginis downgrades aTyr Pharma (NASDAQ:ATYR) from Buy to Neutral.

 atyr-pharma-stock-sinks-plans-fda-review-after-mixed-phase-3-results

ATyr Pharma's stock dips after Phase 3 trial of efzofitimod misses steroid reduction goal, but shows improvements in lung f...

Core News & Articles

Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, although c...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION